Commercial Prognostic Tests for Prostate Cancer May Not Be Accurate in African American Men
PHILADELPHIA — Commercial gene expression tests that guide treatment decisions for prostate cancer may not accurately predict risk of...
PHILADELPHIA — Commercial gene expression tests that guide treatment decisions for prostate cancer may not accurately predict risk of...
PHILADELPHIA — The associations of breast cancer recurrence scores (RS) with mortality measured using Oncotype DX, a commercial diagnostic...
PHILADELPHIA — Almost 40 percent of patients with metastatic melanoma harboring BRAF V600E mutations who were treated with a...
PHILADELPHIA – ADCT-402, an investigational antibody-drug conjugate, showed signs of clinical activity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma,...
PHILADELPHIA – Combining an investigational anti-GD2 monoclonal antibody with induction chemotherapy yielded promising two-year event-free survival in pediatric patients...
Rates show significant variation by geographic regions for these groups than for whites PHILADELPHIA: The nation’s American Indian and...
PHILADELPHIA – Patients with metastatic colorectal cancer harboring a subset of non-V600 mutations in the BRAF gene, known as...
Test employs error correction to increase accuracy PHILADELPHIA – A new liquid biopsy test could detect microsatellite instability (MSI)...
PHILADELPHIA – The PARP inhibitor olaparib (Lynparza) in combination with the chemotherapeutic agent temozolomide (Temodar) showed clinical efficacy in...
PHILADELPHIA – Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high...